03.10.2024 • NewsSK PharmtecoinvestmentSmall Molecules

SK Pharmteco to Expand Production in South Korea

South Korean contract development and manufacturing organization (CDMO) SK Pharmteco announced a major expansion of its small molecule and peptide production capabilities with a $260 million investment to construct a new facility in Sejong, South Korea.

Scheduled to begin operations in late 2026, the new facility will be the fifth plant the company opens in South Korea. According to SK Pharmteco, it will span 135,800 square feet and feature eight production trains with an output of tens of metric tons annually. The investment also includes peptide R&D facilities, CGMP kilo labs, and CGMP pilot plant for peptide manufacturing. With these resources, SK Pharmteco said that it can support early-stage clinical and commercial production with great flexibility. SK Pharmteco plans to hire over 300 new employees at the Sejong site.

Another part of the investment is the construction of the shell for a sixth manufacturing plant, which will allow a quick expansion of capacity in the future.

Joerg Ahlgrimm, CEO of SK Pharmteco, said: “By investing in this new facility, we’re increasing our capacity in Asia in line with our global expansion strategy and solidifying our position as a trusted partner for companies developing groundbreaking treatments, demonstrating our adaptability and reliability in a rapidly changing industry.”

“Our new facility represents a significant investment in our future and a commitment to delivering exceptional value to our customers,” said Yongwoo Park, SK Pharmteco’s president, Small Molecule, Asia. “By expanding our capacity and capabilities, we can offer even faster turnaround times, increased flexibility, and a higher level of quality.”

SK Pharmteco’s current site in Sejong, South Korea. © SK Pharmteco
SK Pharmteco’s current site in Sejong, South Korea. © SK Pharmteco

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.